Skip to main content

Table 1 Inclusion and exclusion criteria for patients

From: Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Inclusion Criteria
 • Outpatients 18 to 60 years of age.
 • DSM-IV-TR criteria for MDE in MDD, as confirmed by the MINI.
 • Depressive episode duration ≥3 months.
 • Free of psychotropic medications for at least 5 half-lives (i.e. 1 week for most antidepressants, 5 weeks for fluoxetine) before baseline.
 • Score ≥24 on the MADRS.
 • Fluent in English, sufficient to complete the interviews and self-report questionnaires.
Exclusion Criteria
 • Diagnosis of Bipolar I or Bipolar II disorder.
 • Any other psychiatric diagnosis that is considered the primary diagnosis.
 • Any significant personality disorder diagnosis (e.g., borderline, antisocial) that might interfere with participation in the protocol, defined by clinician judgment.
 • High suicidal risk, defined by clinician judgment.
 • Substance dependence/abuse in the past 6 months.
 • Significant neurological disorders, head trauma, or other unstable medical conditions.
 • Pregnant or breastfeeding.
 • Psychosis in the current episode.
 • High risk for hypomanic switch (i.e., history of antidepressant-induced hypomania).
 • Failed 4 or more adequate pharmacologic interventions (as determined by the ATHF).
 • Previously failed or showed intolerance to escitalopram or aripiprazole.
 • Started psychological treatment within the past 3 months with the intent of continuing treatment.
 • Contraindications to MRI.
  1. DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; MDE, Major Depressive Episode; MDD, Major Depressive Disorder; MINI, Mini International Neuropsychiatric Interview; MADRS, Montgomery-Åsberg Depression Rating Scale; ATHF, Antidepressant Treatment History Form